米兰系统唾液腺细胞病理报告:观察者间可靠性评估
该研究在美国北卡罗来纳大学回顾2010-2017年有后续手术切除的唾液腺细针穿刺(FNA)病例,将原细胞学结果转换为米兰系统(MSRSGC)类别,并评估AUS与SUMP两类的观察者间可靠性。结果显示AUS与SUMP的恶性风险均为33%,AUS的Fleiss κ为0.217(P<.05),SUMP的Fleiss κ为0.024(P=.74)。
要点
- AUS与SUMP的恶性风险均为33%,但AUS的肿瘤风险为56%、SUMP为100%。
- AUS类别观察者间一致性为fair(Fleiss κ=0.217,P<.05)。
- SUMP类别观察者间一致性为slight(Fleiss κ=0.024,P=.74)。
核心结论
- 研究评估MSRSGC各类别的观察者间可靠性,发现AUS为fair一致、SUMP为slight一致。
- 观察者倾向将SUMP病例判为AUS或良性肿瘤类别,可能因对SUMP作为诊断选项不熟悉。
- 新报告系统初始采用需质量评估以确保其可靠且对临床有用。
研究设计与样本
- 回顾性检索2010-2017年有后续手术切除的唾液腺FNA病例,以组织学诊断为金标准比较。
- 将原细胞学结果转换为MSRSGC类别(nondiagnostic、nonneoplastic、AUS、benign neoplasm、SUMP、suspicious、malignant)。
- 观察者间可靠性评估选取23例,富集AUS(n=11)或SUMP(n=9)病例。
- 由6名boarded cytopathologists和1名cytopathology fellow评估代表性切片并给出MSRSGC诊断。
- 采用Fleiss' κ系数确定观察者间可靠性。
主要发现
- AUS与SUMP病例的恶性风险(ROM)均为33%。
- AUS病例的肿瘤风险为56%,SUMP病例的肿瘤风险为100%。
- AUS类别Fleiss κ为0.217(P<.05),SUMP类别Fleiss κ为0.024(P=.74)。
关键数值与推荐
- AUS与SUMP的ROM均为33%,AUS肿瘤风险56%、SUMP肿瘤风险100%。
- AUS类别Fleiss κ=0.217(P<.05),SUMP类别Fleiss κ=0.024(P=.74)。
临床怎么用
- 采用MSRSGC报告唾液腺FNA时,应关注AUS与SUMP类别观察者间一致性较低的问题。
- 对新报告系统初始采用应开展质量评估,确保其对临床可靠有用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) has been proposed to standardize salivary gland fine-needle aspiration (FNA) diagnoses. This study assessed salivary gland FNA results and risk of malignancy (ROM) rates at the University of North Carolina as well as the interobserver reliability (IOR) of the atypia of undetermined significance (AUS) and salivary gland neoplasm of uncertain malignant potential (SUMP) categories. METHODS: The electronic medical record was searched for FNA cases from 2010 to 2017 with subsequent surgical resections. Histologic diagnosis was used for gold-standard comparison. The original cytologic results were then converted into MSRSGC categories (nondiagnostic, nonneoplastic, AUS, benign neoplasm, SUMP, suspicious, and malignant). For the assessment of IOR, 23 cases were selected with enrichment for cases diagnosed as AUS (n = 11) or SUMP (n = 9). Six boarded cytopathologists and 1 cytopathology fellow assessed representative slides and provided an MSRSGC diagnosis for each case. Fleiss' κ coefficients were calculated to determine IOR. RESULTS: The ROM was 33% for both AUS and SUMP cases; however, the risk of neoplasia was 56% for AUS cases and 100% for SUMP cases. Fleiss' κ for the AUS category was 0.217 (P < .05), and Fleiss' κ for the SUMP category was 0.024 (P = .74). CONCLUSIONS: In this study assessing the IOR of MSRSGC categories, fair agreement and slight agreement were found for the AUS and SUMP categories, respectively. Observers preferentially used the AUS or benign neoplasm category for SUMP cases, perhaps because of unfamiliarity with SUMP as a diagnostic option. The initial adoption of a new reporting system will require a quality assessment to ensure that the system is reliable and useful for clinicians. Cancer Cytopathol 2018;126:390-6. © 2018 American Cancer Society.
引用
- Hollyfield JM, O'Connor SM, Maygarden SJ, et al. Northern Italy in the American South: Assessing interobserver reliability within the Milan System for Reporting Salivary Gland Cytopathology. Cancer Cytopathol. 2018. PMID: 29579353. doi:10.1002/cncy.21989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。